The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

SureCN13907084     (8S,9R,13S,14S,17S)-17- ethanoyl-10,13...

Synonyms: AC1LA4XF, A809329, Pregna-4,6-diene-3,20-dione, (9b)-
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of dydrogesterone


Psychiatry related information on dydrogesterone


High impact information on dydrogesterone


Chemical compound and disease context of dydrogesterone


Biological context of dydrogesterone


Anatomical context of dydrogesterone


Associations of dydrogesterone with other chemical compounds


Gene context of dydrogesterone

  • Additionally, an increase in Th2-type and a decrease in Th1-type cytokines could be detected in vitro after incubation with dydrogesterone [6].
  • Replacement with dydrogesterone, a synthetic analog of P4 at a dose of 4 mg/day s.c. restored the magnitude of nocturnal PRL surges [26].
  • Human osteoblast-like (HOB) cells were incubated with 17 beta-estradiol (E2), progesterone (P), dydrogesterone (DD), 20 alpha-dihydroxydydrogesterone (DHD), with and without the growth factors, insulin-like growth factors-I/-II (IGF-I/-II) or transforming growth factor-beta type 1 (TGF-beta 1) for 24 h under serum-free conditions [27].
  • After dydrogesterone supplementation, mean TNF-alpha/IL-10 ratio changed from 1.08 to 1.75 while IL-12/IL-10 ratio remained almost the same (0.56-0.61) in the threatened aborters group and did not differ from those in healthy women [28].
  • Further, dydrogesterone increased levels of plasma PIBF in stressed mice, but did not affect progesterone levels [29].

Analytical, diagnostic and therapeutic context of dydrogesterone


  1. Premenstrual syndrome. A double-blind cross-over study of treatment with dydrogesterone and placebo. Sampson, G.A., Heathcote, P.R., Wordsworth, J., Prescott, P., Hodgson, A. The British journal of psychiatry : the journal of mental science. (1988) [Pubmed]
  2. Dydrogesterone in threatened abortion: pregnancy outcome. Omar, M.H., Mashita, M.K., Lim, P.S., Jamil, M.A. J. Steroid Biochem. Mol. Biol. (2005) [Pubmed]
  3. The role of dydrogesterone in recurrent (habitual) abortion. Gruber, C.J., Huber, J.C. J. Steroid Biochem. Mol. Biol. (2005) [Pubmed]
  4. Dydrogesterone and endometriosis. Johnston, W.I. British journal of obstetrics and gynaecology. (1976) [Pubmed]
  5. Dydrogesterone in the reduction of recurrent spontaneous abortion. El-Zibdeh, M.Y. J. Steroid Biochem. Mol. Biol. (2005) [Pubmed]
  6. The progesterone derivative dydrogesterone down-regulates neurokinin 1 receptor expression on lymphocytes, induces a Th2 skew and exerts hypoalgesic effects in mice. Orsal, A.S., Blois, S., Labuz, D., Peters, E.M., Schaefer, M., Arck, P.C. J. Mol. Med. (2006) [Pubmed]
  7. The effect of dydrogesterone on premenstrual symptoms. A double-blind, randomized, placebo-controlled study in general practice. Hoffmann, V., Pedersen, P.A., Philip, J., Fly, P., Pedersen, C. Scandinavian journal of primary health care. (1988) [Pubmed]
  8. Depletion of CD8+ cells abolishes the pregnancy protective effect of progesterone substitution with dydrogesterone in mice by altering the Th1/Th2 cytokine profile. Blois, S.M., Joachim, R., Kandil, J., Margni, R., Tometten, M., Klapp, B.F., Arck, P.C. J. Immunol. (2004) [Pubmed]
  9. Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenopausal women. Post, M.S., Verhoeven, M.O., van der Mooren, M.J., Kenemans, P., Stehouwer, C.D., Teerlink, T. J. Clin. Endocrinol. Metab. (2003) [Pubmed]
  10. Estrogen replacement therapy continuously combined with four different dosages of dydrogesterone: effect on calcium and lipid metabolism. Voetberg, G.A., Netelenbos, J.C., Kenemans, P., Peters-Muller, E.R., van de Weijer, P.H. J. Clin. Endocrinol. Metab. (1994) [Pubmed]
  11. Endometrial cytosolic and nuclear progesterone receptors in the luteal phase defect. Jacobs, M.H., Balasch, J., Gonźalez-Merlo, J.M., Vanrell, J.A., Wheeler, C., Strauss, J.F., Blasco, L., Wheeler, J.E., Lyttle, C.R. J. Clin. Endocrinol. Metab. (1987) [Pubmed]
  12. Differential effect of transdermal estrogen plus progestagen replacement therapy on insulin metabolism in postmenopausal women: relation to their insulinemic secretion. Cucinelli, F., Paparella, P., Soranna, L., Barini, A., Cinque, B., Mancuso, S., Lanzone, A. Eur. J. Endocrinol. (1999) [Pubmed]
  13. Effect of CNS depressants and stimulants on latency for the appearance of copulatory response in the female rat. Carrer, H., Meyerson, B.J. Pharmacol. Biochem. Behav. (1976) [Pubmed]
  14. Uteroplacental circulation in early pregnancy complicated by threatened abortion supplemented with vaginal micronized progesterone or oral dydrogesterone. Czajkowski, K., Sienko, J., Mogilinski, M., Bros, M., Szczecina, R., Czajkowska, A. Fertil. Steril. (2007) [Pubmed]
  15. Endometrial, physical and psychological effects of postmenopausal oestrogen therapy with added dydrogesterone. Siddle, N.C., Fraser, D., Whitehead, M.I., Jesinger, D.K., Endacott, J., Prescott, P., Pryse-Davies, J. British journal of obstetrics and gynaecology. (1990) [Pubmed]
  16. The effect of dydrogesterone on the mid-cycle gonadotrophin surge in regularly cycling women. Lenton, E.A. Clin. Endocrinol. (Oxf) (1984) [Pubmed]
  17. Dydrogesterone increases serum lactalbumin concentration in the puerperium. Martin, R.H., El Sheikh, M.A., Chapman, C. Clin. Endocrinol. (Oxf) (1983) [Pubmed]
  18. Bone effects of dydrogesterone in ovariectomized rats: a biologic, histomorphometric, and densitometric study. Roux, C., Kolta, S., Chappard, C., Morieux, C., Dougados, M., De Vernejoul, M.C. Bone (1996) [Pubmed]
  19. Effects of dydrogesterone on the oestrogenized postmenopausal endometrium. Lane, G., Siddle, N.C., Ryder, T.A., Pryse-Davies, J., King, R.J., Whitehead, M.I. British journal of obstetrics and gynaecology. (1986) [Pubmed]
  20. The effect of HRT on cerebral haemodynamics and cerebral vasomotor reactivity in post-menopausal women. Bain, C.A., Walters, M.R., Lees, K.R., Lumsden, M.A. Hum. Reprod. (2004) [Pubmed]
  21. Hormone replacement therapy with dydrogesterone and 17 beta-oestradiol: effects on serum lipoproteins and glucose tolerance during 24 month follow up. Crook, D., Godsland, I.F., Hull, J., Stevenson, J.C. British journal of obstetrics and gynaecology. (1997) [Pubmed]
  22. Comparison of transvaginal ultrasonography and endometrial biopsy in endometrial surveillance in postmenopausal HRT users. Hänggi, W., Bersinger, N., Altermatt, H.J., Birkhäuser, M.H. Maturitas. (1997) [Pubmed]
  23. The endometrial nucleolar channel system as an indicator of progestin potency in HRT. Ryder, T.A., Mobberley, M.A., Whitehead, M.I. Maturitas. (1995) [Pubmed]
  24. Androgenic progestogens oppose the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in postmenopausal women. Preliminary report. Campagnoli, C., Biglia, N., Lanza, M.G., Lesca, L., Peris, C., Sismondi, P. Maturitas. (1994) [Pubmed]
  25. Clinical study comparing the effects of sequential hormone replacement therapy with oestradiol/dydrogesterone and conjugated equine oestrogen/norgestrel on lipids and symptoms. Cieraad, D., Conradt, C., Jesinger, D., Bakowski, M. Arch. Gynecol. Obstet. (2006) [Pubmed]
  26. Replacement of progesterone restores the nocturnal surge of prolactin following suppression with a gonadotropin-releasing hormone agonist during early pregnancy in the rat. Joseph, I.B., Sridaran, R. Life Sci. (1991) [Pubmed]
  27. Comparison of the action of 17 beta-estradiol and progestins with insulin-like growth factors-I/-II and transforming growth factor-beta 1 on the growth of normal adult human bone-forming cells. Verhaar, H.J., Damen, C.A., Duursma, S.A., Scheven, B.A. Maturitas. (1995) [Pubmed]
  28. The impact of dydrogesterone supplementation on serum cytokine profile in women with threatened abortion. Kalinka, J., Radwan, M. Am. J. Reprod. Immunol. (2006) [Pubmed]
  29. The progesterone derivative dydrogesterone abrogates murine stress-triggered abortion by inducing a Th2 biased local immune response. Joachim, R., Zenclussen, A.C., Polgar, B., Douglas, A.J., Fest, S., Knackstedt, M., Klapp, B.F., Arck, P.C. Steroids (2003) [Pubmed]
  30. Analysis of the contribution of dydrogesterone to bone turnover changes in postmenopausal women commencing hormone replacement therapy. Tobias, J.H., Clarke, S., Mitchell, K., Robins, S., Amer, H., Fraser, W.D. J. Clin. Endocrinol. Metab. (2001) [Pubmed]
  31. Pharmacodynamics of follicle stimulating hormone (FSH) in postmenopausal women during pulsed estrogen therapy: Evidence that FSH release and synthesis are controlled by distinct pathways. Christin-Maitre, S., Laveille, C., Collette, J., Brion, N., Reginster, J.Y. J. Clin. Endocrinol. Metab. (2003) [Pubmed]
  32. Relationship of estradiol levels to breakthrough bleeding during continuous combined hormone replacement therapy. van de Weijer, P.H., Barentsen, R., de Vries, M., Kenemans, P. Obstetrics and gynecology. (1999) [Pubmed]
  33. A prospective randomized trial of human chorionic gonadotrophin or dydrogesterone support following in-vitro fertilization and embryo transfer. Kupferminc, M.J., Lessing, J.B., Amit, A., Yovel, I., David, M.P., Peyser, M.R. Hum. Reprod. (1990) [Pubmed]
WikiGenes - Universities